source
- Novo Nordisk halts two cardiovascular trials of inflammation-targeting drug ziltivekimabNovo Nordisk announced it is halting the HERMES and ATHENA cardiovascular trials of its experimental drug ziltivekimab, which was intended to lower inflammation to improve heart health. A data mon…
- ADARx, backed by AbbVie, files for IPO to fund clinical-stage siRNA programsADARx Pharmaceuticals, a San Diego biotech supported by AbbVie, announced plans to pursue an initial public offering. The company says most of the IPO proceeds will be used to advance three clinic…